Wilson Disease (WD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Wilson Disease (WD) is an inherited disorder characterized by an abnormality in copper metabolism. It results from specific mutations in the ATP7B gene, which encodes a protein called ATP7B responsible for copper transportation and regulation. This gene mutation can occur as homozygous or compounds heterozygous mutations. ATP7B plays a vital role in excreting excess copper into bile and facilitating the synthesis of ceruloplasmin, a key copper-transporting protein in the bloodstream. The liver serves as the primary site for managing dietary copper, and in individuals with WD, impaired ATP7B function leads to copper accumulation within liver cells, causing liver-related issues.
·
The prevalence of Wilson's disease varies
across regions, with around 31 to 37 cases per 100,000 individuals in EU
countries, 48 to 59 cases in the USA, and 33 cases per 1,000,000 individuals in
Japan.
Thelansis’s
“Wilson Disease (WD) Market Outlook, Epidemiology, Competitive Landscape, and
Market Forecast Report – 2023 To 2033" covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Wilson
Disease (WD) treatment modalities options for eight major markets (USA,
Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Wilson Disease (WD)
across 8 MM market from the centre of Excellence/ Public/ Private hospitals
participated in the study. Insights around current treatment landscape,
epidemiology, clinical characteristics, future treatment paradigm, and Unmet
needs.
Wilson
Disease (WD) Market Forecast Patient Based Forecast Model (MS. Excel Based
Automated Dashboard), which Data Inputs with sourcing, Market Event, and
Product Event, Country specific Forecast Model, Market uptake and patient share
uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing
scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Tags: Wilson
Disease (WD), Wilson Disease (WD) market outlook, Wilson
Disease (WD) competitive landscape, Wilson
Disease (WD) market forecast, Thelansis, Primary
market research, KOL insights, Competitive Intelligence (CI)
Comments
Post a Comment